Figure 2. Immunohistochemical analysis of K561 dimethylation of HSP70 in various cancer tissues.

(a,b) Immunohistochemical analysis of K561-dimethylated HSP70 levels in clinical tissue using anti-HSP70 K561me2 in bladder (a), lung (b) and kidney (c) cancer tissue microarrays. Detailed clinical information is described in Supplementary Tables S6, S7 and S8. (d) Immunohistochemical analysis of the K561 dimethylation status of HSP70 using a large number of NSCLC clinical tissues. Tissue sections were incubated with a rabbit anti-HSP70 K561me2 polyclonal antibody followed by HRP-conjugated secondary antibody (Dako). Three typical stained cases are shown. Staining intensity for each case is categorized into one of three patterns: 0 (no staining), 1 (weak staining), 2 (moderate to strong staining). (e,f) Distribution of K561 dimethylation status of HSP70 in NSCLC clinical tissues classified by the T-factor (e) and the N-factor (f).